{"DataElement":{"publicId":"3179441","version":"1","preferredName":"Person Concomitant Agent QTcB Prolongation Greater Than 500 msec Torsades De Pointes Increase Risk Clinical Trial Eligibility Criteria Ind-3b","preferredDefinition":"the yes/no/not applicable indicator whether a person has received any pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study that may increase the risk of QTc prolongation, a time interval between the start of the Q wave and the end of the T wave in the cardiac cycle longer than 500 msec, or Torsades De Pointes, an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"3179220v1.0:2958018v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3179220","version":"1","preferredName":"Person Concomitant Agent QTcB Prolongation Greater Than 500 msec Torsades De Pointes Increase Risk Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person receiving any pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study that may increase the risk of QTc prolongation, a time interval between the start of the Q wave and the end of the T wave in the cardiac cycle longer than 500 msec, or Torsades De Pointes, an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3179218v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3179218","version":"1","preferredName":"Concomitant Agent QTcB Prolongation Greater Than 500 msec Torsades De Pointes Increase Risk Clinical Trial Eligibility Criteria","preferredDefinition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.:Corrected QT interval longer than 500 msec, in accordance with Bazett's correction formula.:An atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline. In addition the QRS complex displays a periodic waxing and waning of amplitude on the electrogram. (NCI):Increase; a process of becoming larger or more numerous or more important.:Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia):Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3179218v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Agent","conceptCode":"C70902","definition":"A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol's complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"QTcB Prolongation Greater Than 500 msec","conceptCode":"C71096","definition":"Corrected QT interval longer than 500 msec, in accordance with Bazett's correction formula.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Torsades De Pointes by ECG Finding","conceptCode":"C50779","definition":"An electrocardiographic finding of an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline, occurring in the setting of a prolonged QT interval. In addition, the QRS complex displays a periodic waxing and waning of amplitude on the electrocardiogram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Increase","conceptCode":"C25533","definition":"A process of becoming larger, more numerous, more important, or more likely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98800737-B88D-738F-E040-BB89AD436509","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98800737-B89E-738F-E040-BB89AD436509","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000430","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000429","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104905","version":"1","longName":"GOG-0186I","context":"NRG"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[{"name":"3179220v1.0:2958018v1.0","type":"USED_BY","context":"NRG"},{"name":"3179220v1.0:2958018v1.0","type":"USED_BY","context":"Alliance"},{"name":"ABTC","type":"USED_BY","context":"ABTC"}],"ReferenceDocuments":[{"name":"Medications that may prolong","type":"Preferred Question Text","description":"Medications that may prolong QTc and/or Torsades de Pointes","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Does the patient require any drug known to prolong QTc interval, including anti-arrhythmic medication?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Does the patient require any drug known to prolong QTc interval, including anti-arrhythmic medication (with the exception of patients already receiving stable dose regimens of antidepressants of the SSRI class prior to enrollment)?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Does the patient have a correct QT interval calculated by the Fridericia formula (QTcF) greater than 500 ms?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Does the patient have a corrected QT interval calculated by the Fridericia formula (QTcF) greater than 500 ms within 28 days before randomization?","url":null,"context":"CTEP"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Does the patient require a therapy with a drug known to prolong the QT/QTc interval?","url":null,"context":"ABTC"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior medications with a known risk to prolong the QTc interval and/or cause Torsades de Pointes?","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9893B0AF-DC98-D85D-E040-BB89AD43541E","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-29","modifiedBy":"MORENOC","dateModified":"2018-10-19","changeDescription":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}